Sign in

Myelodysplastic syndromes

Current status: Treatable, not yet curable

A group of blood cancers in which the bone marrow makes blood cells that do not grow into healthy ones. Too few healthy blood cells can lead to infection, anaemia or easy bleeding. Treatment ranges from blood transfusions and medicines to strong chemotherapy with a stem cell transplant, which can cure some people. It is rare and more likely after age 60, or after chemotherapy or radiotherapy for another cancer.

Read more about myelodysplastic syndromes
Where research stands todayUpdated 18 Nov 2026

Trial-stage treatments and research studies you can joinOpen trials for referral

Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.

Filters

Country
City
Distance is calculated in your browser. Your city is not sent to us.
Type
Get notified of new trialsGermany, all cities, all phases
Your ageShows only trials that take people your age.
Phase
  1. Trial-stage treatmentPhase 3Taking people
    Tests venetoclax with chemotherapy for newly diagnosed acute myeloid leukemia

    Tests venetoclax added to chemotherapy in adults newly diagnosed with acute myeloid leukemia.

    Arnsberg, GermanyAlso Aschaffenburg, Bad Saarow, Berlin, Bonn, Bremen, Darmstadt, Dortmund, Giessen, …Age 18 to 75
  2. Trial-stage treatmentPhase 2Taking people
    Venetoclax Added to Pre-Transplant Treatment for Blood Cancers

    Tests venetoclax with treosulfan before stem cell transplant in adults with leukemia or myelodysplastic syndrome.

    GermanyAge 18 to 75
  3. Trial-stage treatmentPhase 3Taking people
    Tests elritercept in adults with myelodysplastic syndromes needing regular blood transfusions

    Tests elritercept against placebo in adults with low-risk myelodysplastic syndromes needing transfusions.

    Berlin, GermanyAlso Bonn, Leipzig, MagdeburgAge 18+
  4. Trial-stage treatmentPhase 3Soon in Germany
    Elritercept Compared With Epoetin Alfa for Anemia in Lower Risk Myelodysplastic Syndromes

    Compares elritercept with epoetin alfa for anemia in adults with myelodysplastic syndrome needing transfusions.

    Bayreuth, GermanyAlso BerlinAge 18+
  5. Trial-stage treatmentPhase 1/2Taking people
    Tests AZD3632 alone or with other drugs in advanced blood cancers

    Tests the oral drug AZD3632 in adults with advanced leukemia or myelodysplastic syndromes.

    Dresden, GermanyAlso Frankfurt Am Main, Heidelberg, Munich, UlmAge 16+
  6. Trial-stage treatmentPhase 2
    Tests elritercept for anemia in adults with lower-risk myelodysplastic syndromes

    Tests elritercept at different doses for anemia in adults with lower-risk MDS.

    Bayreuth, GermanyAlso Berlin, Bonn, Esslingen am Neckar, MainzAge 18+
  7. Trial-stage treatmentPhase 2
    Tests pacritinib in adults with VEXAS syndrome, a rare inflammatory disease

    Tests pacritinib against placebo in adults with VEXAS syndrome, an inflammatory condition.

    Dresden, GermanyAlso Düsseldorf, Hamburg, Lübeck, Munich, TübingenAge 18+
  8. Trial-stage treatmentPhase 3Taking people
    Tests lisaftoclax with azacitidine for newly diagnosed higher-risk myelodysplastic syndrome

    Tests lisaftoclax plus azacitidine against placebo in adults with newly diagnosed higher-risk myelodysplastic syndrome.

    Berlin, GermanyAlso Dresden, Leipzig, Stuttgart, UlmAge 18+
  9. Trial-stage treatmentPhase 2/3Taking people
    Tests oral ASTX030 alone or with venetoclax in myeloid blood cancers

    Tests an oral form of azacitidine, alone or with venetoclax, in adults with blood cancers.

    Freiburg im Breisgau, GermanyAlso HeidelbergAge 18+
  10. Trial-stage treatmentPhase 1/2Taking people
    Venetoclax added to pre-transplant treatment for blood cancers

    Tests venetoclax with chemotherapy before stem cell transplant in adults with myelodysplastic syndromes or leukemia.

    Aachen, GermanyAlso Cologne, JenaAge 18+
  11. Trial-stage treatmentPhase 2
    Tests bezuclastinib in adults with advanced systemic mastocytosis

    Tests bezuclastinib in adults with advanced systemic mastocytosis, a rare blood disease.

    Aachen, GermanyAlso Freiburg im Breisgau, Lübeck, MannheimAge 18+
  12. Trial-stage treatmentPhase 1/2Taking people
    Tests BGB-11417 alone or with azacitidine in myeloid blood cancers

    Tests BGB-11417, alone or with azacitidine, in adults with acute myeloid leukemia or MDS.

    Leipzig, GermanyAlso UlmAge 18+
  13. Trial-stage treatmentPhase 3Taking people
    Compares ivosidenib and azacitidine in people with IDH1-mutated myelodysplastic syndromes

    Compares two treatments in adults with myelodysplastic syndromes who have an IDH1 gene change.

    Dresden, GermanyAlso Hanover, LeipzigAge 18+
  14. Trial-stage treatmentPhase 2Taking people
    Comparing two preparation drugs before stem cell transplant for leukemia and MDS

    Compares two chemotherapy preparation drugs before stem cell transplant in adults with AML or MDS.

    Aachen, GermanyAlso Augsburg, Berlin, Chemnitz, Cologne, Dresden, Frankfurt am Main, Greifswald, Halle, …Age 18+
  15. Trial-stage treatmentPhase 2Taking people
    Tests ivosidenib after stem cell transplant in IDH1-mutated leukemia

    Tests ivosidenib as maintenance after transplant in adults with IDH1-mutated AML or MDS.

    Aachen, GermanyAlso Chemnitz, Dresden, Erlangen, Essen, Frankfurt Am Main, Greifswald, Hamburg, Jena, …Age 18 to 75
  16. Trial-stage treatmentPhase 2
    Continued ASTX727 treatment for people from earlier studies with blood cancers

    Gives continued ASTX727 to adults with blood cancers who benefited from earlier studies.

    GermanyAge 18+
  17. Trial-stage treatmentPhase 1/2Soon in Germany
    Testing S241656 alone or with other drugs in certain blood cancers

    Tests S241656 for safety in adults with relapsed or hard-to-treat myeloid leukemias.

    Berlin, GermanyAlso Dresden, Heidelberg, Jena, Leipzig, UlmAge 18+
  18. Trial-stage treatmentPhase 3
    Long-term safety of luspatercept in people from earlier luspatercept studies

    Continues luspatercept treatment and follow-up in adults with anemia-related blood disorders.

    Berlin, GermanyAlso Dresden, Düsseldorf, Halle, Hamburg, Hanover, Leipzig, Mainz, MünchenAge 18+
  19. Trial-stage treatmentPhase 2Taking people
    Testing momelotinib for anemia caused by low-risk myelodysplastic syndrome

    Tests momelotinib, at different doses, in adults with low-risk myelodysplastic syndrome and anemia.

    Dresden, GermanyAlso Leipzig, MainzAge 18+
  20. Trial-stage treatmentPhase 1/2
    Tests AB8939 in adults with relapsed or refractory acute myeloid leukemia

    Tests the safety of daily AB8939 infusions in adults with acute myeloid leukemia.

    Chemnitz, GermanyAlso LeipzigAge 18+

Search the publications

The results open on the publications page in a new tab, so this page stays as it is.

Lists with this disease filtered

Where treatment stands

Some patients can be cured with strong chemotherapy and a stem cell transplant from a donor. For others, treatment may slow the disease from getting worse.

In the EU, imetelstat and efbemalenograstim alfa were first approved in 2025 and 2024, not always for this disease.

Approved: 13

Officially approved for this disease in the EU, the US, Switzerland or France.

Human testing stage: 11

Being tested in people. Many treatments at this stage are never approved.

Animal testing stage: 3

Worked in animals in a study published in the last 12 months. Most treatments at this stage never reach people.

Support organisations

Patient organisations and helplines in Germany, for you and your family.

Myelodysplastic syndromes organisations in Germany

  • Krebsinformationsdienst (KID) des DKFZ

    Doctors answer cancer questions by phone or e-mail, free, every day from 8:00 to 20:00.

  • Deutsche Krebshilfe

    German non-profit cancer charity providing information on cancer types, early detection, prevention, therapy and self-help, and funding research and patient support.

  • Leukaemiehilfe RHEIN-MAIN e.V.

    Contact and information point for adults with blood cancers: disease information incl. AML, monthly in-person and virtual patient meetings, myeloma and MDS groups, relatives' meetings, podcasts; contact by email.

  • MDS-Patienten Interessengemeinschaft (MDS-Patienten IG)

    MDS-specific patient group run by LHRM e.V. in Rüsselsheim; offers patient representation, contacts, information and virtual meetings for patients and relatives.

General support in Germany

  • TelefonSeelsorge Deutschland

    Free, anonymous 24/7 crisis and emotional support line across Germany (0800 111 0 111, 0800 111 0 222, 116 123), plus chat and e-mail.

  • gesund.bund.de

    The German Federal Ministry of Health's portal providing reliable, quality-assured health information on diseases, care and prevention.

  • Stiftung Unabhängige Patientenberatung Deutschland (UPD)

    Statutory independent foundation giving free advice to patients in Germany on health and health-law questions, including patient rights.

International organisations

  • Aplastic Anemia and MDS International Foundation

    Foundation supporting patients and families with aplastic anemia, MDS and related bone marrow failure diseases.

  • DKMS

    Finds blood stem cell donors worldwide so that people with blood cancer can have a transplant.

  • MDS Foundation

    US-based global nonprofit supporting patients with MDS and related diseases such as AML, their families and providers, with education, resources and support.

Frontlight Community

Myelodysplastic syndromes community in Germany

People living with myelodysplastic syndromes and those close to them share what they went through. Posts are not medical advice: ask your doctor about your own treatment.

Offer tissue or data

There are three ways to help research move faster.

Give tissue or bloodA biobank stores your sample so many research teams can use it.See open programmes
Share your health dataA patient registry collects your health data, without your name, for research.How to join
Take part as a healthy volunteerStudies also need people without the disease, for comparison. Family and friends can help.Volunteer

Approved treatments

17 medicines are approved for myelodysplastic syndromes in at least one of the places we checked. An approval in one place does not mean the medicine is offered or paid for where you live.

Checked on 18 Nov 2026 in the official lists of the US (FDA), the EU (European Commission and EMA) and Switzerland (Swissmedic), which we read every day. The lists of Japan (PMDA, approvals since April 2004), France (ANSM, medicines approved in France only) and Taiwan (TFDA) were checked on 11 Nov 2026. For Canada (Health Canada) and Singapore (HSA) we checked only whether a medicine is sold there, not what for. The French ratings are the opinions of the HAS Transparency Committee, from the French public medicines database (base de données publique des médicaments, newest opinion 10 Dec 2025). 6 uncertain matches are left out. Other countries' own approvals were not checked.

“Miracle cure” fact checker

Social media spreads misinformation. Paste here what you read, and we'll tell you whether there is scientific evidence behind it.

What you paste is checked with AI (Anthropic, USA) and is not stored. Please leave out names and other personal details.

Before you pay for anything, ask three things

  1. Is there a published study in people?
  2. Can I have the full price in writing?
  3. What does my doctor say?

About myelodysplastic syndromes

Sources: NCI PDQ, MedlinePlus, The Lancet Oncology

A group of blood cancers in which the bone marrow makes blood cells that do not grow into healthy ones. Too few healthy blood cells can lead to infection, anaemia or easy bleeding. Treatment ranges from blood transfusions and medicines to strong chemotherapy with a stem cell transplant, which can cure some people. It is rare and more likely after age 60, or after chemotherapy or radiotherapy for another cancer.

What is it?

Myelodysplastic syndromes (MDS) are a group of blood cancers. Normally, stem cells in the bone marrow grow into healthy red cells, white cells and platelets. In MDS many of them do not mature and die in the marrow. This leaves too few healthy blood cells, which can lead to anaemia (too few red cells), infections and bleeding.

MDS is rare and mostly affects older people: half are about 70 or older when they find out. In most people the cause is not known. The risk is higher after chemotherapy or radiotherapy for another cancer, and after contact with tobacco smoke, some chemicals (such as benzene, pesticides or fertilisers) or heavy metals such as lead and mercury.

The first signs

MDS often causes no early signs and is sometimes found by a routine blood test.

  • feeling weak or tired;
  • shortness of breath;
  • skin that is paler than usual;
  • bruising or bleeding easily, or tiny spots under the skin caused by bleeding;
  • fever or infections that keep coming back.

How doctors find out

Blood tests count the red blood cells, white blood cells and platelets. A bone marrow test takes a small sample of marrow with a needle, and a lab checks it for abnormal cells and chromosome changes. Some of these tests, such as checking the chromosomes, help plan treatment.

Current treatment

Treatment depends on several factors. It can include transfusions, medicines that help make red blood cells, and antibiotics for symptoms; lenalidomide or azacitidine and decitabine for some people; and chemotherapy with a donor stem cell transplant for certain patients.

Will it get worse?

Prognosis (chance of recovery) and treatment options depend on certain factors. How it goes depends on how many immature cells (blasts) are in the marrow, how many kinds of blood cells are low, certain chromosome changes, whether it followed earlier cancer treatment, and your age and general health. Some types of MDS can turn into acute myeloid leukaemia (AML).

Medicines: what helps, and what to watch for

Supportive care eases the problems caused by the disease. It can include red blood cell or platelet transfusions, medicines that help the body make more red blood cells, and antibiotics to fight infection. Azacitidine or decitabine can slow the change to AML. Lenalidomide helps some people with a certain chromosome change (del(5q)) need fewer transfusions. People at high risk of AML may get the same chemotherapy as for AML.

Good to know:

  • Many transfusions can build up too much iron in the body and harm organs; medicines can remove the extra iron;
  • You can join a clinical trial before, during or after treatment, and some trials take only people who have not started treatment.

A transplant, for some people

Some people can be cured with strong chemotherapy followed by a stem cell transplant from a donor, which gives them healthy blood-forming cells. It may not work as well when MDS was caused by earlier cancer treatment.

Is there a cure?

For some people, yes: strong chemotherapy with a donor stem cell transplant can cure certain patients. There is no standard treatment when MDS comes back or stops responding. Clinical trials are testing new treatments.

See the 397 trials you can join

Median survival

About 2 years with azacitidine, in higher-risk MDS

Measured in: Higher-risk myelodysplastic syndromes: a phase III trial of azacitidine against conventional care (358 patients)

The figures behind it

Phase III trial in higher-risk myelodysplastic syndromes (358 patients): median overall survival 24.5 months with azacitidine vs 15.0 months with conventional care regimens. Lower-risk MDS is not part of this figure.